Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

Comedian Jim Gaffigan is the first to admit his weight has fluctuated over the years. After reaching 270 lbs., he decided to ...

Company behind weight loss drug Mounjaro, Lilly, has issued an official statement after British woman, Susan McGowan, died ...

Weekly doses of tirzepatide, sold as Zepbound for obesity and Mounjaro for type 2 diabetes, are given. The approved dual GIP ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

Sahpra warns of falsified diabetes treatments Ozempic and Mounjaro sold online for weight loss, posing health risks.

Susan McGowan took two doses of tirzepatide, sold under the brand Mounjaro and nicknamed the “King Kong of weight-loss jabs”, ...

The so-called Mounjaro Meetup is to take place in Glasgow with several prolific users of the medication advertising the event online. The weight-loss drug is a brand-name of tripeptide and has ...

,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is sold under the brand name Mounjaro and affects feelings of hunger and ...